- Home
- RARE vs LFST Comparison
RARE vs LFST Comparison
Compare RARE & LFST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RARE
- LFST
- Stock Information
- Founded
- RARE 2010
- LFST 2015
- Country
- RARE United States
- LFST United States
- Employees
- RARE N/A
- LFST N/A
- Industry
- RARE Biotechnology: Pharmaceutical Preparations
- LFST Medical/Nursing Services
- Sector
- RARE Health Care
- LFST Health Care
- Exchange
- RARE Nasdaq
- LFST Nasdaq
- Market Cap
- RARE 3.6B
- LFST 3.0B
- IPO Year
- RARE 2014
- LFST 2021
- Fundamental
- Price
- RARE $33.84
- LFST $6.63
- Analyst Decision
- RARE Strong Buy
- LFST Buy
- Analyst Count
- RARE 15
- LFST 4
- Target Price
- RARE $95.93
- LFST $8.63
- AVG Volume (30 Days)
- RARE 748.6K
- LFST 2.3M
- Earning Date
- RARE 05-01-2025
- LFST 05-08-2025
- Dividend Yield
- RARE N/A
- LFST N/A
- EPS Growth
- RARE N/A
- LFST N/A
- EPS
- RARE N/A
- LFST N/A
- Revenue
- RARE $560,230,000.00
- LFST $1,250,970,000.00
- Revenue This Year
- RARE $19.15
- LFST $15.35
- Revenue Next Year
- RARE $32.11
- LFST $13.86
- P/E Ratio
- RARE N/A
- LFST N/A
- Revenue Growth
- RARE 29.01
- LFST 18.50
- 52 Week Low
- RARE $33.69
- LFST $4.64
- 52 Week High
- RARE $60.37
- LFST $8.61
- Technical
- Relative Strength Index (RSI)
- RARE 27.75
- LFST 32.91
- Support Level
- RARE $36.71
- LFST $6.52
- Resistance Level
- RARE $39.21
- LFST $6.81
- Average True Range (ATR)
- RARE 1.34
- LFST 0.22
- MACD
- RARE -0.32
- LFST -0.00
- Stochastic Oscillator
- RARE 2.19
- LFST 16.79
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
About LFST LifeStance Health Group Inc.
LifeStance Health Group Inc is a mental healthcare company focused on providing evidence-based, medically driven treatment services for children, adolescents, and adults suffering from a variety of mental health issues in an outpatient care setting, both in-person and through its digital health telemedicine offering.